Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

Published in August the 2025 Advocacy Benchmark Report derived from the Company’s industry-leading digital advocacy solution, VoterVoice. Launched in September an upgraded version of the reporting ...

Q3 2025 Earnings Call Transcript November 5, 2025 Anika Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Q1 2026 Earnings Call Transcript November 6, 2025 Operator: Greetings, and welcome to the Coherent First Quarter Fiscal Year ...

Total Payment Volume increased 26.4% to $13.9 billion in the Third quarter of 2025, compared to $11 billion in the Third quarter of 2024. Excluding Sertifi, Total Payment Volume increased 24.0% to $13 ...

ED Conducts Searches At Six J&K Locations In Narco-Terror Funding Case. Jammu, Nov 6 (IANS) The Enforcement Directorate (ED) ...

PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactionsCompany to host Corporate Update call on ...

Vermilion Energy Inc. ("Vermilion", "We", "Our", "Us" or the "Company") is pleased to report operating and condensed ...

MACOM Technology Solutions Holdings, Inc. ( MTSI) Q4 2025 Earnings Call November 6, 2025 8:30 AM EST Welcome to MACOM's Fourth Fiscal Quarter 2025 Conference Call. This call is being recorded today, ...

Zai Lab Limited today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates. "Zai Lab is entering the next phase of our growth, powered ...

Having already raised $1.12 million in its early rounds and sold over 153.6 million BLAZ tokens, Blazpay is emerging as a top ...

Good afternoon, and welcome to NuScale's Third Quarter 2025 Earnings Results Conference Call. Today's call is being recorded. A replay of today's conference call will be available and accessible on ...